- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Spending Spree on Telehealth Is Winding Down
This year, funding fell from $10.5 billion in the first quarter down to the lowest funding has been at $4.6 billion today, according to a report from HealthcareDive.
Funding for digital health is decreasing back to its lowest levels since 2019. Market adjustments and inflation and interest rates may be to thank.
COVID-19 brought telehealth its biggest break in 2020 when healthcare and much of the world operated and delivered care virtually. At an average of $5.4 billion in funding in 2019, telehealth's worth skyrocketed to its highest of $16.8 billion 2021, being one of the biggest demands in healthcare.
This year, funding fell from $10.5 billion in the first quarter down to the lowest funding has been at $4.6 billion today, according to a report from HealthcareDive.
The decrease in funding is severe for clinical trials tech, telehealth and health IT, though telehealth and health IT continue to see some of the highest funding amounts overall.
According to the report, CB Insights said this year's total telehealth funding is projected to be less than half of what the sector brought in during 2021.
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
